29 research outputs found
Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
Envenomation by caterpillars (erucism): proposal for simple pain relief treatment
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento CientÃfico e Tecnológico (CNPq)Coordenação de Aperfeiçoamento de Pessoal de NÃvel Superior (CAPES
Leprosy: review of the epidemiological, clinical, and etiopathogenic aspects - Part 1
Leprosy is caused by Mycobacterium leprae and has been known since biblical times. It is still endemic in many regions of the world and a public health problem in Brazil. The prevalence rate in 2011 reached 1.54 cases per 10,000 inhabitants in Brazil. The mechanism of transmission of leprosy consists of prolonged close contact between susceptible and genetically predisposed individuals and untreated multibacillary patients. Transmission occurs through inhalation of bacilli present in upper airway secretion. The nasal mucosa is the main entry or exit route of M. leprae. The deeper understanding of the structural and biological characteristics of M. leprae, the sequencing of its genome, along with the advances in understanding the mechanisms of host immune response against the bacilli, dependent on genetic susceptibility, have contributed to the understanding of the pathogenesis, variations in the clinical characteristics, and progression of the disease. This article aims to update dermatologist on epidemiological, clinical, and etiopathogenic leprosy aspects
SBD-RESP na busca ativa de casos de hansenÃase
FUNDAMENTOS: A Sociedade Brasileira de Dermatologia Regional do Estado de São Paulo (SBD-RESP), apoiada pela Fundação Paulista Contra a HansenÃase, e em ação conjunta com os Serviços de Dermatologia do estado de São Paulo, credenciados pela Sociedade Brasileira de Dermatologia, lançou a campanha SBD-RESP na Busca Ativa de Casos de HansenÃase. OBJETIVOS: Auxiliar o Programa Nacional de Controle da HansenÃase no controle da doença. MÉTODO: Todos os Serviços de Dermatologia do estado de São Paulo, credenciados pela Sociedade Brasileira de Dermatologia, foram convidados e os 17 que participaram receberam uma planilha de dados e modelos de materiais informativos sobre a doença. A campanha foi realizada entre os meses de maio e julho de 2010. Ao término do perÃodo, cada serviço encaminhou a planilha de dados para análise estatÃstica. RESULTADOS: Foram examinadas 1718 pessoas e diagnosticados, no total, 90 casos de hansenÃase, a maioria do gênero masculino e da cor branca, com percentuais semelhantes de multibacilares e de paucibacilares. Doze por cento apresentavam história familiar de hansenÃase. O maior número de casos detectados foi na capital, seguido, no interior, pela região de Presidente Prudente. O Ãndice de detecção em menores de 15 anos foi 4%. CONCLUSÕES: Os resultados da campanha mostram a importância desta iniciativa da SBD-RESP. Sugere-se que ações semelhantes sejam repetidas e que se estendam a outras regionais da Sociedade Brasileira de DermatologiaBACKGROUND: The Brazilian Society of Dermatology of the State of São Paulo (SBD-RESP), supported by the São Paulo State Foundation Against Leprosy and acting jointly with São Paulo State Services of Dermatology, accredited by the Brazilian Society of Dermatology, launched the campaign SBD-RESP in active search for leprosy cases. OBJECTIVES: To assist the National Leprosy Control Program in eliminating Hansen's disease. METHODS: All of the São Paulo State Services of Dermatology, accredited by the Brazilian Society of Dermatology, were invited to join the campaign. The 17 Services which accepted to participate received a spreadsheet of data and models of informative materials about the disease. The campaign lasted from May to July 2010. At the end of the campaign, each Service sent the spreadsheet data for statistical analysis. RESULTS: 1,718 people were examined and 90 cases of Hansen's disease were diagnosed. Most of the individuals infected were male and white and presented similar percentages of multibacillary and paucibacillary groups. Twelve percent had a family history of leprosy. The highest number of cases was detected in São Paulo city, followed by the region of Presidente Prudente, located in the countryside of São Paulo State. The detection rate in children younger than 15 years old was 4%. CONCLUSION: The campaign results show the importance of the SBD-RESP initiative. It is suggested that similar actions be repeated and extended to other regional offices of the Brazilian Society of Dermatolog
PREVENCAO DE TROMBOFLEBITES PELO USO DE HEPARINA EM PACIENTES TRATADOS COM ANFOTERICINA B
The authors studied the incidence of thrombophlebitis in 41 patients treated intravenously with amphotericin B. The patients were divided in two different group: Group 1: patients treated with amphotericin B and hydrocortisone with heparin (1000 UI); Group 2: patients treated with amphotericin B and hydrocortisone. The results showed 23.81% of incidence of thrombophlebitis in Group 1 and 90% in Group 2. Thrombophlebitis in Group 1 ranged from mild to moderate without any change during the drug therapy. In Group 2, the incidence was 66.67% and the thrombophlebitis were severe being necessary the withdrawn of the drugs in 35.0% of the cases. We concluded that heparin, in low doses, in association with amphotericin B, was an efficient drug preventing or reducing the development of thrombophlebitis
Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day
BACKGROUND: Leprosy can have its course interrupted by type 1 and 2 reactional episodes, the last named of erythema nodosum leprosum (ENL). Thalidomide has been the medication of choice for the control of ENL episodes since 1965. OBJECTIVES: These episodes can repeat and cause damages to the patient. In order to prevent these episodes, an extra dose of 100 mg/day thalidomide was used during six months, followed by a follow-up period of six more months after thalidomide discontinuation. METHODS: We included 42 patients with multibacillary (MB) leprosy who had episodes of ENL. They were male and female patients aged between 18 and 84 years. RESULTS: Of the 42 patients, 39 (92.85%) had the lepromatous form and three (7.15%) had the borderline form. We found that 100% of patients had no reactional episode during the use of the drug. During the follow-up period after thalidomide discontinuation, 33 (78.57%) patients had no reactional episode and nine (21.43%), all of them with the lepromatous form, had mild episodes, which were controlled using non-steroidal anti-inflammatory. There were no thalidomide-related side effects. CONCLUSION: A maintenance dose of 100 mg/day of thalidomide showed to be effective to prevent repeated type 2 reactional episodes of ENL
Leprosy: a review of laboratory and therapeutic aspects - Part 2
Leprosy is a chronic infectious condition caused by Mycobacterium leprae(M. leprae). It is endemic in many regions of the world and a public health problem in Brazil. Additionally, it presents a wide spectrum of clinical manifestations, which are dependent on the interaction between M. leprae and host, and are related to the degree of immunity to the bacillus. The diagnosis of this disease is a clinical one. However, in some situations laboratory exams are necessary to confirm the diagnosis of leprosy or classify its clinical form. This article aims to update dermatologists on leprosy, through a review of complementary laboratory techniques that can be employed for the diagnosis of leprosy, including Mitsuda intradermal reaction, skin smear microscopy, histopathology, serology, immunohistochemistry, polymerase chain reaction, imaging tests, electromyography, and blood tests. It also aims to explain standard multidrug therapy regimens, the treatment of reactions and resistant cases, immunotherapy with bacillus Calmette-Guérin (BCG) vaccine and chemoprophylaxis
Paracoccidioidomicose em paciente com carcinoma do colo uterino
Os autores relatam caso de paciente do sexo feminino com paracoccidioidomicose, associada a carcinoma do colo uterino estádio IIIB. Paracoccidioidomicose, associada à neoplasia, ocorre entre 0,16% a 14,1% segundo diferentes séries de casos. em casos com neoplasia disseminada a infecção fúngicas pode apresentar comportamento oportunÃsticoThis report describes the case of a female patient with paracoccidioidomycosis associated with a stage IIIB cervical carcinoma. Paracoccidioidomycosis in association with a malignant tumor occurs in 0.16% to 14.1% of cases in accordance with different case series. In cases in which the cancer is disseminated, the fungal infection may behave opportunisticall